Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cellular senescence is an irreversible growth arrest that is activated in normal cells upon shortening of telomere and other cellular stresses. Bypassing cellular senescence is a necessary step for cells to become immortal during oncogenic transformation. During the spontaneous immortalization of Li-Fraumeni Syndrome (LFS) fibroblasts, we found that
CREG1
(Cellular Repressor of E1A-stimulated Genes 1) expression was decreased during immortalization and increased in senescence. Moreover, we found that repression of
CREG1
expression occurs via an epigenetic mechanism, promoter DNA methylation. Ectopic expression of
CREG1
in the immortal LFS cell lines decreases cell proliferation but does not directly induce senescence. We confirmed this in
osteosarcoma
and fibrosarcoma cancer cell lines, cancers commonly seen in Li-Fraumeni Syndrome. In addition, we found that p16 (INK4a) is also downregulated in immortal cells and that coexpression of
CREG1
and p16 (INK4a) , an inhibitor of CDK4/6 and Rb phosphorylation, has a greater effect than either
CREG1
and p16 (INK4a) alone to reduce cell growth, induce cell cycle arrest and cellular senescence in immortal LFS fibroblasts,
osteosarcoma
and fibrosarcoma cell lines. Moreover, cooperation of
CREG1
and p16 (INK4a) inhibits the expression of cyclin A and cyclin B by inhibiting promoter activity thereby decreasing mRNA and protein levels; these proteins are required for S-phase entry and G2/M transition. In conclusion, this is the first evidence to demonstrate that
CREG1
enhances p16 (INK4a) -induced senescence by transcriptional repression of cell cycle-regulated genes.
...
PMID:CREG1 enhances p16(INK4a) -induced cellular senescence. 2126 17